X4 Pharmaceuticals, Inc. (XFOR)

1.2900 +0.0600 (+4.88%) At close: 04:00PM EDT

X4 Pharmaceuticals, Inc.

61 North Beacon Street
4th Floor
Boston, MA 02134
United States
857 529 8300
https://www.x4pharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 93

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Paula Ragan Ph.D.	CEO, President & Director	963.58k	N/A	1970
Mr. Adam S. Mostafa	CFO, Treasurer & Corporate Secretary	699.18k	N/A	1980
Dr. Mary DiBiase Ph.D.	Chief Operating Officer	661.59k	N/A	1961
Dr. Richard Peters M.D., Ph.D.	Founder	N/A	N/A	1963
Dr. Renato T. Skerlj Ph.D.	Founder	N/A	N/A	N/A
Dr. Keith T. Flaherty M.D.	Founder & Member of Corporate Advisory Board	N/A	N/A	1971
Dr. Arthur Taveras Ph.D.	Chief Scientific Officer	N/A	N/A	1964
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Robert David Arbeit	Senior Vice President of Clinical Development and Translational Research	N/A	N/A	1948
Mr. Mark Baldry M.B.A.	Chief Commercial Officer	N/A	N/A	1964

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Corporate governance

X4 Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.